Article date: April 2008
The European pharmacovigilance working party has published a report on the risk of suicidal thoughts and behaviour with antidepressants. The report summarises the data for this risk that has been assessed both within Europe and by the US Food and Drug Administration. The benefits of selective serotonin reuptake inhibitor antidepressant medicines continue to outweigh the risks in their licensed indications.
Article citation: Drug Safety Update April 2008; Vol 1, Issue 9: 10
Published 11 December 2014